Clinical pharmacokinetics of simotinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC patients.

被引：1
|
作者：
Han, Xiaohong
Li, Ning
Hu, Xingsheng
Song, Yuanyuan
Zhang, Yan
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Canc Inst Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e13575
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13575
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I clinical pharmacokinetics, safety and tolerability of simotinib in advanced NSCLC patients with EGFR mutation
    Han, X.
    Li, N.
    Hu, X.
    Song, Y.
    Zhang, Y.
    Shi, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S67 - S68
  • [2] Phase I study of the safety and pharmacokinetics of epitinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced solid tumors
    Zhou, Qing
    Wu, Yi Long
    Yu, Xiyong
    Yang, Jinji
    Wen, Limin
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial
    Hu, Xing-Sheng
    Han, Xiao-Hong
    Yang, Sheng
    Li, Ning
    Wang, Lin
    Song, Yuan-Yuan
    Mu, Hua
    Shi, Yuan-Kai
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4449 - 4459
  • [4] Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor
    Palma, John
    Marchetti, Antonio
    Felicioni, Lara
    De Pas, Tommaso
    Chiari, Rita
    Del Grammastro, Maela
    Filice, Giampaolo
    Ludovini, Vienna
    Brandes, Alba A.
    Chella, Antonio
    Malorgio, Francesco
    Guglielmi, Flavio
    De Tursi, Michele
    Santoro, Armando
    Crino, Lucio
    Buttitta, Fiamma
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S250 - S250
  • [5] OBX02-011, a Novel Oral ALK and EGFR Dual-target Tyrosine Kinase Inhibitor for the Treatment of Advanced NSCLC Patients
    Heo, S.
    Lee, S.
    Ha, T.
    Baek, M.
    Kim, M.
    Jung, K.
    Kim, S. -E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S653 - S653
  • [6] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [7] Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
    Zhao, Qiong
    Shentu, Jianzhong
    Xu, Nong
    Zhou, Jianya
    Yang, Guangdie
    Yao, Yinan
    Tan, Fenlai
    Liu, Dongyang
    Wang, Yingxiang
    Zhou, Jianying
    LUNG CANCER, 2011, 73 (02) : 195 - 202
  • [8] Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
    Shimoda, Yukiko
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S483
  • [9] CLINICAL CHARACTERISTICS, TREATMENT OUTCOMES, AND SAFETY OF EGFR TYROSINE KINASE INHIBITON IN ADVANCED NSCLC PATIENTS POSSESSING AN EGFR MUTATION: THE ALBERTA, CANADA EXPERIENCE
    Humphreys, Michael R.
    Sangha, Randeep S.
    Magliocco, Anthony M.
    Ghosh, Sunita
    Butts, Charles
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1311 - S1312
  • [10] Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC
    Liao, Bin-Chi
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1426 - 1428
12345